Evidence map›Paper›PMID 39872224›Full record

ArticleIntegrated pharmacy research & practice2025

Developing a Prototype Machine Learning Model to Predict Quality of Life Measures in People Living With HIV.

Gabriel Mercadal-Orfila, Joaquin Serrano López de Las Hazas, Melchor Riera-Jaume, Salvador Herrera-Perez

Abstract read
In one paragraph

Article in Integrated pharmacy research & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gabriel Mercadal-OrfilaPharmacy Department, Hospital Mateu Orfila, Maón, Spain.ORCID 0000-0001-7304-458X
Joaquin Serrano López de Las HazasPharmacy Department, Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain.
Melchor Riera-JaumeUnidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
Salvador Herrera-PerezFacultad de Ciencias de la Salud, Universidad Internacional de Valencia, Valencia, España.ORCID 0000-0002-0491-3718

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the realm of Evidence-Based Medicine, introduced by Gordon Guyatt in the early 1990s, the integration of machine learning technologies marks a significant advancement towards more objective, evidence-driven healthcare. Evidence-Based Medicine principles focus on using the best available scientific evidence for clinical decision-making, enhancing healthcare quality and consistency by integrating this evidence with clinician expertise and patient values. Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs) have become essential in evaluating the broader impacts of treatments, especially for chronic conditions like HIV, reflecting patient health and well-being comprehensively. Purpose: The study aims to leverage Machine Learning (ML) technologies to predict health outcomes from PROMs/PREMs data, focusing on people living with HIV. Patients and Methods: Our research utilizes a ML Random Forest Regression to analyze PROMs/PREMs data collected from over 1200 people living with HIV through the NAVETA telemedicine system. Results: The findings demonstrate the potential of ML algorithms to provide precise and consistent predictions of health outcomes, indicating high reliability and effectiveness in clinical settings. Notably, our ALGOPROMIA ML model achieved the highest predictive accuracy for questionnaires such as MOS30 VIH (Adj. Conclusion: The results from our machine learning algorithms are promising for predicting PROMs and PREMs in AIDS settings. This work highlights how integrating ML technologies can enhance clinical pharmaceutical decision-making and support personalized treatment strategies within a multidisciplinary integration framework. Furthermore, leveraging platforms like NAVETA for deploying these models presents a scalable approach to implementation, fostering patient-centered, value-based care.

Indexed as

chronic HIV managementevidence-based medicinemachine-learning in healthcareNAVETAPROMs-PREMs

Identifiers

PMID39872224
PMCPMC11766232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.